PatientsVille.com Logo

Psoriasis and Rodogyl

PatientsVille

Psoriasis Symptoms and Causes

Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people who have Psoriasis also get a form of arthritis called psoriatic arthritis.

A problem with your immune system causes Psoriasis. In a process called cell turnover, skin cells that grow deep in your skin rise to the surface. Normally, this takes a month. In Psoriasis, it happens in just days because your cells rise too fast.

Psoriasis can be hard to diagnose because it can look like other skin diseases. Your doctor might need to look at a small skin sample under a microscope.

Psoriasis can last a long time, even a lifetime. Symptoms come and go. Things that make them worse include

  • Infections
  • Stress
  • Dry skin
  • Certain medicines

Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medicines, and light therapy.

NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

Check out the latest treatments for psoriasis

psoriasis treatment research studies

Rodogyl clinical trials, surveys and public health registries


Find Drug Side Effect reports



Rodogyl Side Effects

Pyrexia (23)
Headache (14)
Urticaria (11)
Pruritus (10)
Rash (8)
Hyperthermia (7)
Vomiting (5)
Hypoaesthesia (4)
Toxic Skin Eruption (4)
Asthenia (4)
Petechiae (4)
Leukocytosis (3)
Dermatitis Bullous (2)
Dermatitis Exfoliative (2)
Gastric Lavage (2)
Haemoglobin Decreased (2)
Hepatocellular Damage (2)
Cholestasis (2)
Gamma-glutamyltransferase Increased (2)
Erythema (2)
Encephalopathy (2)
Diarrhoea (2)
Paraparesis (2)
Neck Pain (2)
Autoimmune Disorder (2)
Rash Maculo-papular (2)
Malaise (2)
Intentional Overdose (2)
Rash Pustular (2)
Tremor (2)
Suicide Attempt (2)
Purpura (1)
Myocarditis (1)
Toxic Epidermal Necrolysis (1)
Thrombocytopenia (1)
Persecutory Delusion (1)
Mitral Valve Incompetence (1)
Pallor (1)
Pancytopenia (1)
Psychotic Disorder (1)
Fixed Eruption (1)
Leukopenia (1)
Kawasaki's Disease (1)
Hallucinations, Mixed (1)
Liver Disorder (1)
Fatigue (1)
Ejection Fraction Decreased (1)
Eosinophilic Pneumonia (1)
Fall (1)
Dyspnoea (1)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Can rodogyl delay your period?

I take yasminelle and now i'm taking rodogyl. Does it effect the pill?

Sudden increase in blood presure

While using rodogyl i experienced mouth trush and swollen lips i still have a red and inflamed line around my lips and my digestion is so bad i have so much acidity now while before i was ok

Abdominal pain, diarrhoea, headache, joint swelling (psoriasis flare), sore eyes, increase in hot flushes.

Accdg to my dermatologist headache and backpain is normal adverse reaction of the medicine,how are you now, I also have a psoriasis, and just recently taken neotigason. you gve me a reply at marlboro212206@gmail.com

Bonjour, Amlor après 8 an de prise journalière de 5mg m'a provoqué un psoriasis facial et de l'ecxema. Ces EI ont ils été observés chez d'autres patients ? bien cordialement

Could my daughters psoriasis have anything to do with her old english sheepdog who urinates everywhere and sleeps in and on her bed?

HI, BRENDA, MY NAME IS GINGER. I ALSO HAVE HAD SEVERE PSORIASIS AND INVERTED PSORIASIS OVER 90 PER CENT OF MY BODY. MY HUSBAND EVEN LEFT ME OVER THE FACT THAT I WAS TERRIBLE TO LOOK AT AND SICK FROM IT. I HAVE A GREAT DERMATOLOGIST WHO TRIED

I am a 31 year old female. I weigh 125 lbs. I took Enbrel on and off for about 3 years for chronic psoriasis. Towards the end of my last treatment and since, I have been diagnosed with chronic accute bronchitis, chronic

I am suffering from daily headaches, my 40dd breasts have become tender and larger(not cool) and my psoriasis has become worse, so I am going to seek an alterative medication for my acid and bile reflux. Qld Australia

I am suffering from Gullate Psoriasis for the past 6 months. Today i am having a neck sprain to which I was suggested to take "Nicip plus" which contains Paracetamol 325 mg and Nimesulide 100 mg. I want to know whether consuming this medici

I am taking triopatal 900 mg a day for past 2 months.i had mild psoriasis earlier which has increasd tremendously since 2 months. any relation between the two

I am use neotigason & suffer from psoriasis what effect to me ?

Psoriasis Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
Conditions: Nail Psoriasis;   Plaque Psoriasis
Interventions: Biological: Adalimumab (ADA);   Other: Placebo
Outcome Measures: Proportion of subjects achieving a total-fingernail modified Nail Psoriasis Severity Index (mNAPSI) 75 response;   For US regulatory purposes: Proportion of subjects with a Physician's Global Assessment of Fingernails of "clear" or "minimal";   For Ex-US sites: Percent change in total mNAPSI of all fingernails;   For Ex-US: Proportion of subjects achieving mNAPSI = 0 in all fingernails;   For Ex-US: Change in Nail Psoriasis Pain Numeric Rating Scale (NRS);   For Ex-US: Change in Nail Psoriasis Physical Functioning Severity Score;   For Ex-US: Proportion of subjects with at least 50% improvement in the scalp component of the Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index (B-SNIPI);   For Ex-US: Proportion of subjects achieving Physician's Global Assessment of Fingernails (PGA-F) of "Clear" or "minimal";   For US: Proportion of subjects acheiving a total mNAPSI 75 response;   For US: Percent change in total mNAPSI of all fingernails;   For US: Proportion of subjects achieving mNAPSI = 0 in all fingernails;   For US: Change in Nail Psoriasis Pain Numeric Rating Scale (NRS);   For US: Change in Nail Psoriasis Physical Functioning Severity Score;   For US: Proportion of subjects with at least 50% improvement in the scalp component of the Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index (B-SNIPI)
2 Recruiting Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab
Condition: Moderate to Severe Plaque-type Psoriasis
Interventions: Drug: Secukinumab (AIN457);   Drug: Placebo
Outcome Measures: Cumulative rate of subjects with Loss of Psoriasis Area and Severity Index (PASI) 75 response up to Week 68;   Change in Psoriasis Area and Severity Index (PASI);   Investigator Global Assessment (IGA) 2011 score;   Time to Psoriasis Area and Severity Index (PASI) 75 response, and;   Hemoglobin count, hematocrit count, red blood cell count, white blood cell count with differential(neutrophils including bands, lymphocytes, monocytes, eosinophils, basophils) and platelet count;   Electrocardiogram (ECG) test results;   Adverse events;   Change in quality of life
3 Recruiting Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis
Conditions: Psoriasis;   Cardiovascular Diseases;   Dyslipidemia
Intervention:
Outcome Measures: Evaluate differences in serum lipid levels in Psoriasis patients compared to controls through the use of a relatively new comprehensive lipid profile test that has not been used in previous Psoriasis studies.;   Compare other cardiovascular biomarkers such as high-sensitivity C-Reactive Protein in Psoriasis patients verses controls.;   Identify if an association exists between the extent and severity of Psoriasis and measured lipid levels
4 Recruiting IL-17 Role in Variants of Psoriasis
Conditions: Scalp Psoriasis;   Pustular Palmo-plantar Psoriasis;   Non-pustular Palmo-plantar Psoriasis;   Elbow Psoriasis;   Lower Leg Psoriasis
Intervention:
Outcome Measures: Source of IL 17A;   Mechanism involved in the IL 17A/IL 23 expression ratio;   Compare IL 17A expression in plaques from scalp against plaques from trunk or lower limbs;   Compare IL 23 expression in plaques from scalp against plaques from trunk or lower limbs;   Compare IL 17A expression in plaques from palms against plaques from trunk or lower limbs;   Compare IL 23 expression in plaques from palms against plaques from trunk or lower limbs;   Compare IL 17A expression in plaques from elbows against plaques from trunk or lower limbs;   Compare IL 23 expression in plaques from elbows against plaques from trunk or lower limbs;   Compare IL 17A expression in plaques from lower legs against plaques from trunk or lower limbs;   Compare IL 23 expression in plaques from lower legs against plaques from trunk or lower limbs;   IL 17A plasma levels of patients with scalp Psoriasis;   IL 17A plasma levels of patients with pustular palmo-plantar Psoriasis;   IL 17A plasma levels of patients with elbow Psoriasis;   IL 17A plasma levels of patients with lower leg Psoriasis;   IL 17A plasma levels of patients with non-pustular palmo-plantar Psoriasis
5 Recruiting Photocil (Topical) for the Treatment of Psoriasis Vulgaris
Condition: Psoriasis
Interventions: Drug: Photocil for Psoriasis;   Other: Placebo - Sunscreen (SPF 2)
Outcome Measure: Psoriasis Area Severity Index (PASI)
6 Recruiting Palmoplantar Pustular Psoriasis Efficacy and Safety wIth Secukinumab
Condition: Palmoplantar Pustular Psoriasis
Interventions: Biological: Secucinumab;   Drug: Placebo
Outcome Measures: palmoplantar pustulosis Psoriasis Area and Severity Index 75 response rate (ppPASI 75);   palmoplantar pustulosis Psoriasis Area and Severity Index response rate (ppPASI);   patient's safety
7 Recruiting Tofacitinib Ointment For Chronic Plaque Psoriasis
Conditions: Psoriasis Vulgaris;   Psoriasis
Interventions: Drug: tofacitinib ointment 20 mg/g;   Drug: tofacitinib ointment 10 mg/g;   Drug: placebo ointment (vehicle)
Outcome Measures: Calculated Physician Global Assessment (PGA-C) of Psoriasis Score;   Gestalt Physician's Global Assessment (PGA-G) of Psoriasis Score;   Change in Psoriasis Area and Severity Index (PASI);   Psoriasis Area and Severity Index 75 (PASI75);   Change in Body Surface Area (BSA) affected with Psoriasis
8 Recruiting Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities
Conditions: Moderate to Severe Plaque Psoriasis;   Antibodies;   Monoclonals
Intervention:
Outcome Measures: To evaluate the effectiveness of Adalimumab over a period of 9 month by analyzing the Psoriasis Area & Severity Index (PASI) in moderate to severe Plaque Psoriasis patients with distinct co-morbidities;   Psoriasis Area & Severity Index (PASI) (=Inclusion visit);   Psoriasis Area & Severity Index (PASI);   Dermatology Life Quality Index (DLQI) (=Inclusion visit);   Dermatology Life Quality Index (DLQI) Subjects will complete a DLQI questionnaire at study visits.;   Evaluation of the prevalence of co-morbidities in consideration of gender (=Inclusion visit);   Life Quality (=Inclusion visit);   Life Quality;   Evaluation of the minimum of clinical important differences (MCID) (=Inclusion visit);   Evaluation of the minimum of clinical important differences (MCID)
9 Recruiting A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis
Conditions: Psoriasis;   Nonalcoholic Fatty Liver Disease
Intervention:
Outcome Measures: Determine the prevalence of NAFLD in Psoriasis patients as compared to controls, via hepatic ultrasonography.;   Evaluate for the presence of other components of the metabolic syndrome in the case and control group by measuring fasting blood glucose, blood pressure, waist circumference, and a lipid profile.;   Identify a possible association between extent and severity of Psoriasis, and the presence of NAFLD.
10 Not yet recruiting Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.
Conditions: Psoriasis;   Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin;   Drug: Gliclazide;   Drug: Sitagliptin matched placebo;   Drug: Gliclazide matched placebo capsule
Outcome Measures: The change in the Psoriasis area and severity index (PASI) in Psoriasis patients with type 2 diabetes treated with sitagliptin and this change in PASI will be compared to patients treated with gliclazide.;   The effects of treatment with sitagliptin and treatment with gliclazide on adverse events.;   The effects of treatment with sitagliptin and treatment with gliclazide on quality of life scores.;   The effects of treatment with sitagliptin and treatment with gliclazide on other efficacy endpoints.;   The effects of treatment with sitagliptin and treatment with gliclazide on cardiovascular profiles.;   The effects of treatment with sitagliptin and treatment with gliclazide on laboratory parameters.;   The change in PASI in Psoriasis patients with type 2 diabetes treated with sitagliptin and this change in PASI will be compared to patients treated with gliclazide.
11 Recruiting A Study Evaluating The Efficacy And Safety oO CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
Condition: Psoriasis
Interventions: Drug: placebo;   Drug: CP-690,550
Outcome Measures: Physician Global Assessment (PGA) of Psoriasis Score;   Psoriasis Area and Severity Index 75 (PASI75) response, the proportion of participants achieving at least 75% reduction in PASI relative to baseline at Week 16;   Dermatology Life Quality Index (DLQI) Total Score
12 Recruiting Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
Condition: Moderate to Severe Nail Psoriasis
Interventions: Biological: secukinumab 150 mg;   Biological: secukinumab 300 mg;   Biological: Placebo
Outcome Measures: Efficacy: change in Nail Psoriasis Severity Index after 16 weeks of treatment. Each treatment group will be compared to placebo;   Efficacy: change in NAPSI over time up to 16 weeks of treatment compared to placebo and over time up to 80 weeks;   Efficacy: change in Psoriasis Area and Severity Index 75 (PASI75) and change in Investigator Global Assessment (IGA mod 2011) over time up to 16 weeks of treatment compared to placebo and over time up to 80 weeks;   Number of subjects in treatment groups 150mg and 300mg with adverse events, safety labs, ECG, and vital signs as a measure of safety and tolerability;   Number and percentage of subjects who develop immunogenicity against secukinumab
13 Recruiting Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Subjects With Moderate-To-Severe Plaque-Type Psoriasis
Conditions: Psoriasis;;   Psoriatic Arthritis;;   Psoriasis Arthropatica
Interventions: Drug: Apremilast;   Drug: Placebo
Outcome Measures: Psoriasis Area and Severity Index-75 (PASI-75).;   Proportion of subject with a Static Physician's Global Assessment (sPGA) score of clear (0) or almost clear (1);   Percent Change from baseline in the Psoriasis affected Body Surface Area (BSA %);   Percent Change in the PASI score;   Proportion of subjects who achieve PASI-50;   Change from baseline in Pruritus Visual Analogue Scale (VAS);   Change from baseline in Dermatology Life Quality Index (DLQI) total score;   Change from baseline in Mental Component Summary (MCS) score of SF-36;   Adverse Events;   For subjects with a diagnosis of psoriatic arthritis at screening: Proportion of subjects who achieve an American College of Rheumatology criteria for a 20% improvement (ACR 20);   For subjects with a diagnosis of psoriatic arthritis at screening: Change from baseline in Psoriatic Arthritis Pain VAS;   For subjects with a diagnosis of psoriatic arthritis at screening: Change from baseline in physical function (Health Assessment Questionnaire Disability Index [HAQ-DI]);   Pharmacokinetics - Cmax;   Pharmacokinetics - Tmax;   Pharmacokinetics - AUC0-8 and AUC0-τ;   Pharmacokinetics - t1/2;   Pharmacokinetics - CLss/F;   Pharmacokinetics - Vss/F;   Population Pharmacokinetics (sparse sampling) - CL/F;   Population Pharmacokinetics (sparse sampling) - Vc/F;   Population Pharmacokinetics (sparse sampling) - KA
14 Recruiting Adalimumab-Psoriasis and Small Bowel Lesions
Conditions: Plaque Psoriasis;   Crohn's Disease
Interventions: Drug: Adalimumab;   Device: Capsule endoscopy
Outcome Measures: Prevalence of small bowel lesions suggestive of Crohn's disease in patients with moderate to severe plaque Psoriasis as visualized by capsule endoscopy;   Induction of mucosal healing at week 24 after initiation of adalimumab in patients with small bowel lesions suggestive of Crohn's disease and Psoriasis as defined by absence of villous edema, erosions and ulcers;   Study the relationship between mucosal healing and plaque Psoriasis improvement in patients with small bowel lesions suggestive of Crohn's disease and Psoriasis;   Study the relationship between levels of fecal calprotectin and endoscopy findings;   Change from baseline in PASI at Week 12 for patients who had presence of small bowel lesions suggestive of CD as compared to patients who did not have small bowel lesions suggestive of CD;   Proportion of patients reaching Psoriasis Area and Severity Index (PASI) 75 at Week 12 for patients who had small bowel lesions suggestive of CD as compared to patients who did not have small bowel lesions suggestive of CD.
15 Recruiting Documentation of Humira in Psoriasis Patients in Routine Clinical Practice
Condition: Moderate to Severe Plaque Psoriasis
Intervention:
Outcome Measures: Exploration of changes in healthcare parameters: number of missed working days due to Psoriasis; number of visits at the doctor's office; number and duration of hospitalizations, self-assessed workability;   Exploration of efficacy in different subgroups regarding: changes in Psoriasis Area and Severity Index; number of patients with Psoriasis Area and Severity Index-75 reduction;   Assessment of safety and tolerability by documenting and analyzing of serious adverse events and adverse events.;   Exploration of the influence of body mass index and weight on efficacy measurement.;   Analysis of the global physician's assessment on Humira treatment;   Assessment on safety and tolerability of Humira - treatment for patient groups with frequent concommitant diseases, especially diabetes type I and II, cardio-vascular and liver and kidney functional impairment and respective concommitant medication.;   Patients' assessment on Humira treatment.
16 Recruiting Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients
Condition: Plaque Psoriasis
Intervention: Drug: M518101
Outcome Measures: Severity of Psoriasis;   Duration of response following 8 week treatment
17 Recruiting PsoBest - The German Psoriasis Registry
Conditions: Psoriasis;   Psoriatic-arthritis
Intervention:
Outcome Measures: Psoriasis Area Severity Index (PASI);   Dermatology Life Quality Index (DLQI)
18 Recruiting Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis
Condition: Psoriasis
Interventions: Drug: etanercept;   Drug: ustekinumab;   Drug: cyclosporine
Outcome Measures: Comparison of effect (improvement or deterioration) of treatment with biological vs. non biological agents on endothelial function in Psoriasis;   Comparison of effect (improvement or deterioration) of treatment with biological vs. non biological agents on vascular function in Psoriasis;   Comparison of effect (improvement or deterioration) of treatment with biological vs. non biological agents on cardiac function in Psoriasis;   Differences and similarities in endothelial function between Psoriasis and control groups;   Differences and similarities in vascular function between Psoriasis and control groups;   Differences and similarities in cardiac function between Psoriasis and control groups
19 Unknown  Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2
Condition: Psoriasis Vulgaris
Interventions: Drug: Triptergium Wilfordii;   Drug: Acitretin
Outcome Measures: Change from baseline in plaque Psoriasis as assessed by PASI(Psoriasis area and severity index) response or PASI 75 (a patient that has an improvement from baseline PASI of at least 75%);   Change from baseline in plaque Psoriasis as assessed by PASI response or PASI 50 (a patient that has an improvement from baseline PASI of at least 50%);   Change from baseline in plaque Psoriasis as assessed by PASI response or PASI 90 (a patient that has an improvement from baseline PASI of at least 90%);   Laboratory parameters, rates of AEs, and percentage of patients requiring interruption or discontinuation of study drug due to AEs
20 Recruiting Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Condition: Psoriasis
Interventions: Biological: Ustekinumab;   Biological: Abatacept;   Drug: Placebo for Ustekinumab;   Drug: Placebo for Abatecept
Outcome Measures: The proportion of participants who experience a Psoriasis relapse at any time between week 12 and week 88;   The proportion of randomized participants who experience a Psoriasis disease relapse prior to week 40.;   The proportion of participants who experience a Psoriasis disease relapse between week 28 and week 88.;   The proportion of participants who experience a Psoriasis disease relapse between week 40 and week 88.;   Mean length of time after week 12 to Psoriasis relapse.;   Physician's Global Assessment (PGA) of cleared or minimal at week 40 and week 88.;   Dermatology Life Quality Index (DLQI);   Frequency and severity of all AEs and SAEs.